NCT01484860View on ClinicalTrials.gov

Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

PHASE2TerminatedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Adenocarcinoma of the PancreasMetastatic Disease

Interventions

DRUG

AUY922

AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University Health Network, Toronto

OTHER